KT809

KT809 is an investigational gene therapy designed for the treatment of Duchenne muscular dystrophy (DMD). It is based on a proprietary adeno-associated virus (AAV) vector platform, specifically utilizing the sixth-generation MyoAAV-LD 6.1 capsid, which is engineered to target skeletal muscle and heart tissue while minimizing delivery to the liver. The therapy delivers a shortened version of the dystrophin gene (microdystrophin) to restore functional protein expression in affected tissues. Preclinical studies have demonstrated that KT809 achieves high and consistent microdystrophin expression in both skeletal and cardiac muscles at lower doses compared to existing therapies, with significantly reduced off-target effects in the liver. The approach aims for improved efficacy and safety over current DMD gene therapies[2][3][4][5]. As of mid-2024, KT809 remains in preclinical development.